Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1975 Dec;20(12):1135-41.
doi: 10.1007/BF01070757.

Early clinical experience with metiamide, a histamine H2-receptor antagonist, in patients with duodenal ulcer

M H Thompson, J D Reed, G Dale, C W Venables
Clinical Trial

Early clinical experience with metiamide, a histamine H2-receptor antagonist, in patients with duodenal ulcer

M H Thompson et al. Am J Dig Dis. 1975 Dec.

Abstract

The clinical, endoscopic, and biochemical effects of metiamide, a histamine H2-receptor antagonist, in therapeutic dosage have been studied in a 28-day open trial in patients with duodenal ulcer disease. A good symptomatic response, combined with a 72% ulcer healing rate was observed. There were small but significant rises in plasma creatinine, serum glutamic oxaloacetic transaminase, and serum lactate dehydrogenase during treatment. Small quantities of amino acids appeared in the urine, and the heart size increased slightly. It is concluded that histamine H2-receptor antagonism may be an important therapeutic approach to duodenal ulcer disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Arch Int Pharmacodyn Ther. 1974 May;209(1):144-9 - PubMed
    1. Br Med J. 1974 Aug 31;3(5930):554-6 - PubMed
    1. Lancet. 1974 Apr 20;1(7860):693-4 - PubMed
    1. Nature. 1972 Apr 21;236(5347):385-90 - PubMed
    1. Gut. 1974 Mar;15(3):189-93 - PubMed

Publication types